Protalix BioTherapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.01 | $0.05 | +600.0% | Beat |
| Q12026 FY2026 | $-0.01 | $0.22 | +2300.0% | Beat |
| Q42025 FY2025 | $0.01 | $-0.07 | -800.0% | Miss |
Back to PLX overview · PLX holders · PLX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.